MX2015000446A - Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue. - Google Patents

Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.

Info

Publication number
MX2015000446A
MX2015000446A MX2015000446A MX2015000446A MX2015000446A MX 2015000446 A MX2015000446 A MX 2015000446A MX 2015000446 A MX2015000446 A MX 2015000446A MX 2015000446 A MX2015000446 A MX 2015000446A MX 2015000446 A MX2015000446 A MX 2015000446A
Authority
MX
Mexico
Prior art keywords
vaccine compositions
virus infection
dengue virus
against dengue
prevention against
Prior art date
Application number
MX2015000446A
Other languages
English (en)
Inventor
Jean Lang
Jiansheng Yao
Yves Girerd-Chambaz
Isabelle Legastelois
Nathalie Mantel
VéRONIQUE BARBAN
Bruno Guy
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2015000446A publication Critical patent/MX2015000446A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a composiciones de vacuna que son útiles en un método para proteger un sujeto humano contra la enfermedad del dengue.
MX2015000446A 2012-07-24 2013-07-24 Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue. MX2015000446A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305908 2012-07-24
EP12305911 2012-07-25
PCT/EP2013/065669 WO2014016362A1 (en) 2012-07-24 2013-07-24 Vaccine compositions for prevention against dengue virus infection

Publications (1)

Publication Number Publication Date
MX2015000446A true MX2015000446A (es) 2015-03-12

Family

ID=48856641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000446A MX2015000446A (es) 2012-07-24 2013-07-24 Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.

Country Status (15)

Country Link
US (1) US20150265695A1 (es)
EP (1) EP2877207A1 (es)
JP (1) JP2015524422A (es)
KR (1) KR20150036593A (es)
CN (1) CN104812408A (es)
AU (1) AU2013295016A1 (es)
BR (1) BR112015001313A2 (es)
CA (1) CA2878599A1 (es)
GT (1) GT201500005A (es)
HK (1) HK1212905A1 (es)
MX (1) MX2015000446A (es)
PE (1) PE20150356A1 (es)
PH (1) PH12014502875A1 (es)
SG (1) SG11201500439RA (es)
WO (1) WO2014016362A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061507T2 (hu) 2013-03-15 2023-07-28 Takeda Vaccines Inc Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz
BR112015031226A2 (pt) * 2013-06-21 2017-08-29 Merck Sharp & Dohme Composição de vacina, e, uso da composição de vacina
TW201620546A (zh) * 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
CA2960102C (en) * 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
WO2016106107A2 (en) 2014-12-22 2016-06-30 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
EP3331559A4 (en) 2015-08-03 2019-03-06 The United States of America as represented by the Secretary of the Army, Walter Reed Army Institute Of Research (WRAIR) PROTEIN OF RECOMBINANT DENGUE ENHANCING IMMUNITY
MX2018004016A (es) * 2015-09-29 2018-11-29 Merial Inc Vacunas de particulas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos.
WO2018208741A1 (en) 2017-05-08 2018-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
EP3730620A4 (en) 2017-12-21 2022-01-05 Green Biomed, Inc. CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION
US20220226401A1 (en) 2018-09-05 2022-07-21 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP2251036A1 (en) 1997-02-28 2010-11-17 Sanofi Pasteur Biologics Co. Chimeric flavivirus vaccines
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
ES2201551T3 (es) 1997-09-05 2004-03-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2000057904A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
CA2365728A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
AU4040200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
JP2002540171A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱４型ウイルスワクチン
CN1384877B (zh) * 1999-08-02 2010-10-27 惠氏 从cDNA拯救腮腺炎病毒
WO2001060847A2 (en) 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
EP1159968B1 (fr) 2000-05-30 2008-10-29 Mahidol University Souches atténuées du virus de la Dengue et leur utilisation dans une composition vaccinale
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
KR100921592B1 (ko) * 2001-06-01 2009-10-14 사노피 파스테르 바이오로직스 씨오 키메라 플라비바이러스 벡터
AU2002330672A1 (en) 2001-07-25 2003-02-17 Genset S.A. Gmg-1 polynucleotides and polypeptides and uses thereof
DK1554301T3 (da) * 2002-05-03 2011-01-24 Us Health Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
BRPI0414443A (pt) * 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
KR101582163B1 (ko) * 2005-06-17 2016-01-05 사노피 파스퇴르 약독화된 뎅기 혈청형 2 균주
WO2006134433A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
JP5227172B2 (ja) 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
US8591916B2 (en) * 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
WO2009134717A1 (en) * 2008-04-30 2009-11-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
WO2011013097A2 (en) * 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
US8900596B2 (en) * 2009-11-18 2014-12-02 The Board Of Regents Of The University Of Texas System Physicochemical (PCP) based consensus sequences and uses thereof
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
CN102906266A (zh) * 2010-05-21 2013-01-30 高等教育联邦系统-匹兹堡大学 登革病毒通用序列及其使用方法
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
MY197723A (en) * 2012-07-24 2023-07-10 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection

Also Published As

Publication number Publication date
WO2014016362A1 (en) 2014-01-30
PE20150356A1 (es) 2015-03-20
JP2015524422A (ja) 2015-08-24
GT201500005A (es) 2015-10-13
EP2877207A1 (en) 2015-06-03
BR112015001313A2 (pt) 2017-08-01
SG11201500439RA (en) 2015-02-27
HK1212905A1 (zh) 2016-06-24
US20150265695A1 (en) 2015-09-24
PH12014502875A1 (en) 2015-02-23
CN104812408A (zh) 2015-07-29
KR20150036593A (ko) 2015-04-07
CA2878599A1 (en) 2014-01-30
AU2013295016A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
PH12018501515B1 (en) Parenteral novovirus vaccine formulations
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
UA115231C2 (uk) Сполуки імідазопіролідинонів
IN2014DN10670A (es)
SG10201704908SA (en) Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP2931310A4 (en) COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
IL236476A0 (en) Preparations and methods for the treatment or prevention of infection with the pneumovirus and diseases related to it
PH12014502065A1 (en) Vesicular formulations
SG10201702292YA (en) Novel attenuated dengue virus strains for vaccine application
MX2015004115A (es) Formas cristalinas de derivados de dihidropirimidina.
ZA201307019B (en) Compositions for preventing and/or treating and infection by an hiv-1 virus
EP2969006A4 (en) COMPOSITIONS AND METHODS FOR TREATING INFECTION WITH IMMUNODEFICIENCY VIRUSES
HK1215682A1 (zh) 用於治療或預防齲齒的組合物、用途和方法
ZA201503844B (en) Compositions and methods for treating dental caries
KR101501876B9 (ko) 자일리톨을 유효성분으로 함유하는 인플루엔자 바이러스 감염증 예방 또는 치료용 조성물
EP2934578A4 (en) VACCINES FOR TREATING CANCER AND COMPOSITIONS FOR IMPROVING VACCINE EFFICIENCY
EP2723372A4 (en) PROTECTION AGAINST DENGUE VIRUS AND PREVENTION AGAINST HEAVY DENGUE ILLNESSES
IN2012DE00826A (es)
IN2013MU03317A (es)
IN2015MN00091A (es)
HK1209647A1 (en) Dengue virus vaccine composition
ZA201407866B (en) Composition for the prevention and treatment of viral infections caused by retroviruses